AARTIDRUGS Aarti Drugs Q1 FY27 results (Apr–Jun 2026) and concall
Aarti Drugs delivered a strong Q1 FY27, with consolidated revenue growing 19% and EBITDA expanding 120 bps to 13.8%, driven by improved API realizations and volume growth. The company maintained stable operations despite global geopolitical challenges and raw material price pressures. Strategic investments in capacity expansion at Sayakha and Baddi, along with plans for Metformin USFDA capacity, are progressing, though the salicylic acid business faces challenges due to anti-dumping duty delays.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 19.0%, net profit down 7.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 598 | 557 | 677 | 591 | 653 +9% | 602 +8% | 720 +6% | 703 +19% |
| EBITDA | 67 | 62 | 93 | 74 | 84 +25% | 55 −11% | 96 +3% | 98 +32% |
| Net profit | 35 | 37 | 63 | 54 | 45 +29% | 41 +11% | 55 −13% | 50 −7% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
